drugset / Trial / NCT00968617
A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will define an effective starting dose for subcutaneous administration of MK2578 to correct anemia in erythropoiesis-stimulating agent (ESA)-naive patients with chronic kidney disease (CKD) who are not on dialysis while evaluating its safety.
Timeline
- Start
- 2009-11
- Primary completion
- 2010-04
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darbepoetin alfa | Protein / enzyme biologic | — | — |
| Subject | MK2578 | Unknown | 1 ug/kg | Subcutaneous |
| Subject | MK2578 | Unknown | 2 ug/kg | Subcutaneous |
| Subject | MK2578 | Unknown | 3.6 ug/kg | Subcutaneous |